Drugmaker Roche had got Emergency Use Authorization from the U.S. Food and Drug Administration for a trial to rapidly detect whether a patient has SARS-CoV-2 or one of two forms of influenza, the company said today.
“With the approaching flu season, this new test is particularly important as SARS-CoV-2 and influenza infections can hardly be differentiated by symptoms alone. Now, with a single test, healthcare professionals can confidently provide the right diagnosis and most effective treatment plan for their patients,” Roche diagnostics head Thomas Schinecker said in a statement.
